<DOC>
	<DOCNO>NCT00019760</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness melphalan give isolated hepatic perfusion follow chemotherapy infuse liver patient unresectable colorectal cancer metastatic liver .</brief_summary>
	<brief_title>Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy Treating Patients With Unresectable Colorectal Cancer That Metastatic Liver</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate response duration patient unresectable colorectal cancer metastatic liver treat isolated hepatic perfusion melphalan follow postoperative hepatic arterial chemotherapy . II . Determine pattern recurrence patient population treatment regimen . III . Evaluate disease-free survival overall survival patient . IV . Evaluate health relate quality life determine whether baseline correlate length survival . PROTOCOL OUTLINE : Patients undergo surgery hyperthermic isolate hepatic perfusion melphalan give intra-arterially 60 minute . At six week post-hepatic perfusion , patient receive floxuridine leucovorin calcium intra-arterially continuous infusion 14 day . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess prior study followup visit . Patients follow every 3-4 month 3 year every 6 month thereafter disease progression . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically cytologically proven measurable metastatic colorectal cancer limit parenchyma liver No evidence unresectable extrahepatic disease Limited resectable extrahepatic disease allow Unresectable liver disease define : Greater 3 site liver disease OR Bilobar disease OR Tumor abut major vascular ductal structure , impede resection preservation liver function OR Limited extrahepatic disease No biopsyproven cirrhosis No significant portal hypertension Prior/Concurrent Therapy Biologic therapy : At least 4 week since prior biologic therapy colorectal cancer recover Chemotherapy : At least 4 week since prior chemotherapy colorectal cancer recover No prior intrahepatic arterial infusional therapy use floxuridine Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy colorectal cancer recover Surgery : See Disease Characteristics Other : No concurrent immunosuppressive drug No concurrent chronic anticoagulant Patient Characteristics Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm3 Hematocrit great 27.0 % WBC great 3,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL PT great 2 second upper limit normal Elevated hepatic transaminase secondary liver metastasis allow No venoocclusive disease Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No congestive heart failure LVEF le 40 % Pulmonary : No chronic obstructive pulmonary disease No chronic pulmonary disease pulmonary function test le 50 % predict Other : No active infection HIV negative Body weight great 30 kg Not pregnant nursing Negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>gastrointestinal cancer</keyword>
	<keyword>genetic condition</keyword>
	<keyword>liver intrahepatic biliary tract cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>site , metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage , colon cancer</keyword>
	<keyword>stage , rectal cancer</keyword>
	<keyword>unclassified/other cancer</keyword>
</DOC>